Live Breaking News & Updates on Valneva Lyme|Page 4

Stay updated with breaking news from Valneva lyme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

21st Austria weekly - Valneva, Vienna Stock Exchange (29/12/2023)

21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer ....

Austriacard Holdinge , Deerfield Management Company , Vienna Stock Exchange , Chief Financial Officer , Stock Exchange , Kapsch Trafficcom , Pierer Mobility Gruppe , Husqvarna Motorcycles , Besuchen Sie , Ic1 Valneva , R Amp D , Company Amp Rsquo S , 2024 The , Covid 19 , B Amp Uuml Hler ,

Valneva says EU regulator accepts its chikungunya vaccine application

The EMA "has determined that all essential regulatory elements required for scientific assessment were included in the application," Valneva said in a statement. Accelerated assessment reduces the timeframe the EMA review to 150 days from 210 days, Valneva said. ....

Olivier Sorgho , European Medicines Agency ,

FDA approves world's first vaccine for 'emerging global health threat': 'Prevention of a potentially debilitating disease'

Valneva said it hopes to commercialize the vaccine in the U.S. early next year. ....

United States , Peter Marks , Advisory Committee On Immunization Practices , European Centre For Disease Prevention , Drug Administration , Accelerated Approval , East African , European Centre , Disease Prevention , Southeast Asia , Advisory Committee , Immunization Practices , Biologics Evaluation , Food And Drug Administration , Chikungunya Virus , Biotech Company , Mosquito Bites , Accelerated Approval Pathway ,

Valneva single-dose chikungunya vaccine poised to 'revolutionize' global health

Valneva recently received the greenlight for IXCHIQ by the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya vaccine. ....

Stephanie Kurdach , Instituto Butantan , European Medicines Agency , Us Advisory Committee On Immunization Practices , Immunization Practices , Bavarian Nordic , Breakthrough Therapy , Fast Track , Bio Developments , Emerging Markets ,

21st Austria weekly - Wienerberger, Valneva, Palfinger (09/11/2023)

21st Austria weekly - Wienerberger Valneva Palfinger 09/11/2023 [pic1]Wienerberger: Operating in a persistently challenging macroeconomic environment provider of innovative ecological solutions for the entire building envelope successfully held its ground third quarter 2023 sustaining good performance first two quarters. Compared to record-breaking year 2022 company generated strong results especially view decline demand all relevant end markets with third-quarter revenues at group level € 3 286 million Q3 2022: 3 848 million and operating EBITDA 665 820 million. The continuation established self-help program aimed earnings growth efficiency enhancements contributed satisfactory amount earnings. These solid results once more demonstrate resilience sustainable diversified business model. Given position proven resilience combined profitability-increasing measures is confident delivering very 2023 confirms target 800-820 million.Wienerberger: performance: 1.91% Valnev ....

United States , Ulstein Verft , Nexans Aurora , Montana Aerospace , Chief Financial Officer , Nexans Marine Operations , Palfinger Marine , Besuchen Sie , Ic1 Wienerberger , Million Wienerberger , Company Amp Rsquo S , Covid 19 ,